Short Interest in Fidelity Disruptive Medicine ETF (NASDAQ:FMED) Grows By 495.7%

Fidelity Disruptive Medicine ETF (NASDAQ:FMED) was the recipient of a significant increase in short interest in the month of August. As of August 31st, there was short interest totaling 6,541 shares, an increase of 495.7% from the August 15th total of 1,098 shares. Based on an average daily trading volume, of 7,438 shares, the short-interest ratio is currently 0.9 days. Approximately 0.4% of the shares of the stock are short sold.

Fidelity Disruptive Medicine ETF Trading Up 0.6%

Shares of Fidelity Disruptive Medicine ETF stock traded up $0.20 on Friday, reaching $31.04. The stock had a trading volume of 485 shares, compared to its average volume of 10,668. Fidelity Disruptive Medicine ETF has a 1 year low of $23.48 and a 1 year high of $32.89. The company has a market cap of $49.66 million, a P/E ratio of 41.33 and a beta of 0.77. The business’s 50 day moving average is $30.14 and its two-hundred day moving average is $27.01.

Institutional Trading of Fidelity Disruptive Medicine ETF

Institutional investors and hedge funds have recently bought and sold shares of the company. Jane Street Group LLC increased its position in shares of Fidelity Disruptive Medicine ETF by 95.4% in the fourth quarter. Jane Street Group LLC now owns 91,414 shares of the company’s stock worth $2,473,000 after purchasing an additional 44,630 shares during the last quarter. Citadel Advisors LLC bought a new stake in Fidelity Disruptive Medicine ETF during the second quarter valued at approximately $282,000. Vise Technologies Inc. bought a new stake in Fidelity Disruptive Medicine ETF during the fourth quarter valued at approximately $234,000. Finally, Virtu Financial LLC purchased a new position in Fidelity Disruptive Medicine ETF in the 4th quarter worth approximately $228,000.

Fidelity Disruptive Medicine ETF Company Profile

The Fidelity Disruptive Medicine ETF (FMED) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that invests in companies involved in disruptive innovation in Health Care. The fund invests in securities of domestic and foreign issuers FMED was launched on Apr 16, 2020 and is managed by Fidelity.